Bladder cancer surveillance timing after tumor removal surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how often veterans with a past high-grade bladder tumor should have follow-up exams (cystoscopy) to check for recurrence. It aims to find the best schedule to keep you safe and reduce unnecessary procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a VA patient who has had a high-grade non-muscle-invasive bladder tumor removed recently.
- You had the standard treatment after your last surgery, like a second look or bladder medicine.
- Your first follow-up cystoscopy at 3 months showed no new tumors and no suspicious urine cells.
- You have not had muscle-invasive bladder cancer or certain other rare bladder cancers.
- You are able to stay in the study for at least 5 years and can consent in English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for people with early-stage bladder cancer that has a low chance of coming back: either careful monitoring without immediate treatment, or receiving chemotherapy directly into the bladder to lower the risk of recurrence. It aims to see if monitoring alone is as good as chemotherapy for those with a low risk detected by a urine test.
This study follows people with past bladder cancer to see how bladder cancer comes back over time. You would provide urine samples at several visits, which helps researchers evaluate urine tests that may spot recurrence earlier.
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Hear when a new High-Grade Early-Stage Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.